| Title : Integrated lipidomic and proteomic profiling reveals metabolic network disruption by SARS-CoV-2 variants - Farley_2025_J.Lipid.Res__100860 |
| Author(s) : Farley SE , Kyle JE , Jahn H , Bramer LM , Piehowski PD , Shepmoes AA , Kaiser BL , Williams SM , Eder JG , Schultz C , Tafesse FG |
| Ref : J Lipid Res , :100860 , 2025 |
|
Abstract :
The rapid evolution of SARS-CoV-2 has produced myriad viral strains with increasing transmissibility and capacity for immune evasion. While effective vaccination campaigns have reduced the fatalities associated with SARS-CoV-2, infections continue, and a detailed understanding of how this virus manipulates host biochemical pathways remains elusive. We asked both whether the patterns of host lipid rewiring remained consistent across variants and whether the changes in the abundance of lipid classes are related to changes in the expression of the enzymes involved in their biosynthesis. We compared global nontargeted lipidomics on A549-ACE2 cells infected with the delta variant (B.1.617.2), or the omicron (B.1.1.529) variant to our previous results of global nontargeted lipidomics on A549-ACE2 cells infected with the original WA1 strain, and further performed quantitative proteomics to assess changes in the host proteome. We found that metabolic rewiring, both on the lipid and the enzymatic level, is remarkably consistent across all three variants. We further mapped changes in the expression of host metabolic enzymes, linking enzyme expression to alterations in the abundance of specific lipids during infection. This analysis identified key proteins related to virus-mediated changes in lipid abundance, including fatty acid synthase (FASN), lysosomal acid lipase (LIPA), and ORMDL, a regulator of sphingolipid biosynthesis. These integrated lipidomic and proteomic experiments shed light on the importance of the complex network of host metabolism networks that support SARS-CoV-2 infection, and suggest that lipid metabolism may be a promising avenue for uncovering conserved therapeutic targets. |
| PubMedSearch : Farley_2025_J.Lipid.Res__100860 |
| PubMedID: 40659247 |
Farley SE, Kyle JE, Jahn H, Bramer LM, Piehowski PD, Shepmoes AA, Kaiser BL, Williams SM, Eder JG, Schultz C, Tafesse FG (2025)
Integrated lipidomic and proteomic profiling reveals metabolic network disruption by SARS-CoV-2 variants
J Lipid Res
:100860
Farley SE, Kyle JE, Jahn H, Bramer LM, Piehowski PD, Shepmoes AA, Kaiser BL, Williams SM, Eder JG, Schultz C, Tafesse FG (2025)
J Lipid Res
:100860